Vanguard High Dividend Yield Index Fund is a strong core holding due to its low expense ratio, consistent dividend growth, ...

Health stocks slumped on Friday as Wall Street weighed the impact that prominent vaccine skeptic Robert F. Kennedy Jr. could ...

President-elect Donald Trump has announced he wants to appoint vaccine sceptic Robert F Kennedy Jr as the head of the US ...

VEGF bispecifics. | Merck and BioNTech are buying Chinese biotechs to gain PD-(L)1/VEGF bispecifics. AstraZeneca's CEO argued ...

The U.S. Food and Drug Administration approved the Keytruda combination in malignant pleural mesothelioma in September. Keytruda, a cancer drug that harnesses a patient's immune system to fight tumors ...

The Dow Jones Industrial Average (DJIA), one of the three main Wall Street benchmarks, succumbed to selling pressure in early ...

Now, it's up to the European Commission to confirm those potential green lights in the coming weeks and months.

In October, Merck took up an option on the personalised RNA-based cancer vaccine with an upfront payment of $250 million as part of a collaboration first agreed in 2016 and expanded in 2018.

Roche’s Tecentriq still has the market for front-line immunotherapy of triple-negative breast cancer (TNBC) to itself, but maybe not for long after Merck & Co reported good results with its ...

Merck MRK announced that it has entered into an exclusive licensing deal with China-based privately-held biotech company ...

Merck (MRK) announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use, or CHMP, adopted an opinion ...

Shares of Merck Merck & Co. Inc. and Amgen Amgen Inc. are contributing to the blue-chip gauge's intraday decline, as the Dow Dow Jones Industrial Average was most recently trading 168 points, or 0.4%, ...